CÁNCER DE MAMA LUMINAL
TIPO
ENSAYO
FASE
ESTADO
ADYUVANCIA
EMBER 4: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)
Fase 3
CERRADO
ADYUVANCIA
GO42784 (LIDERA):A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician’s Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Fase 3
CERRADO
ADYUVANCIA
ADAPLATE:Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
Fase 3
CERRADO
NEOADYUVANCIA
MK756: Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Fase 3
CERRADO
METASTÁSICO
VIKTORIA:Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Fase 3
CERRADO
METASTÁSICO
MK2870-010: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Fase 3
CERRADO
METASTÁSICO
WINB: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
Fase 1
ON HOLD
METASTÁSICO
SABINA: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
Fase 2
CERRADO
METASTÁSICO
ELEVATE: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Fase 1B – 2
CERRADO
METASTÁSICO
DESTINY BREAST 15: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Fase 3
ABIERTO
METASTÁSICO
FOURLIGHT-3: Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Fase 3
CERRADO
METASTÁSICO
BT8009-201: Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Fase 2
CERRADO
METASTÁSICO
DYNASTY-BREAST 02: A Study of DB-1303/BNT323 vs Investigator’s Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Fase 3
CERRADO
CÁNCER DE MAMA TRIPLE NEGATIVO
TIPO
ENSAYO
FASE
ESTADO
NEOADYUVANCIA
TELESCOPE: Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
Fase 2
CERRADO
NEOADYUVANCIA
TROPION02: A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Fase 3
CERRADO
METASTÁSICO
SABINA: PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
Fase 2
CERRADO
METASTÁSICO
WINB: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer
Fase 1
ON HOLD
METASTÁSICO
BT8009-201: Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer
Fase 2
ABIERTO
METASTÁSICO
TROPION02:A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
Fase 2
CERRADO
CÁNCER DE HER 2 POSITIVO
TIPO
ENSAYO
FASE
ESTADO
NEOADYUVANCIA
PHERGAIN: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer
Fase 2
CERRADO
NEOADYUVANCIA
EMPOWHER-208: A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Fase 2
ON HOLD
METASTÁSICO
TUXEDO-3: HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease
Fase 2
CERRADO
METASTÁSICO
TUXEDO-4: A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Fase 2
CERRADO
METASTÁSICO
DEMETHER: PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
Fase 2
CERRADO
METASTÁSICO
ZN-A-1041: A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
Fase 1
CERRADO
METASTÁSICO
ELVN-002: ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Fase 1
CERRADO